Mallinckrodt announces new chief financial officer
19 March 2019 -

Mallinckrodt plc (NYSE: MNK), a global specialty pharmaceutical company, announced yesterday that, following an extensive search, Bryan Reasons has been appointed chief financial officer (CFO), effective immediately.

Reasons will join Mallinckrodt's Executive Committee, the company's senior leadership group, and report directly to president and chief executive officer, Mark Trudeau. George Kegler, who has served as interim CFO at the company, will stay on for a transitional period to ensure a smooth transfer of responsibilities prior to retiring from the company.

Reasons brings broad financial leadership experience to Mallinckrodt, which he gained in publicly traded pharmaceutical companies. Serving as senior vice president and chief financial officer for six years at Impax Laboratories. Reasons was instrumental in the company's 2018 combination with Amneal Pharmaceuticals Inc. He began his 25-year finance career in auditing with PricewaterhouseCoopers, and then progressed through roles of increasing finance responsibility at E I Du Pont De Nemours and Company and Cephalon Inc. He also serves as an independent board director and audit committee chair for both Aclaris Therapeutics Inc and Recro Pharma Inc.

Mark Trudeau said, 'As Mallinckrodt progresses toward the creation of two strategically focused public entities with the anticipated separation of the Specialty Generics and Amitiza(R) segment, it is critical that we have a seasoned leader in the chief financial officer role to help guide us through this transformation. We are pleased to bring someone of Bryan's calibre on board, and believe his background and industry experience will help us meet these near-term needs. Longer term, we expect he will provide exceptional leadership as we become wholly focused on our vision to be an innovation-driven, specialty pharmaceutical growth company focused on improving outcomes for underserved patients with severe and critical conditions.'